 |
|
|
| |
Optimization of an Interferon-free Hepatitis C Virus Therapy Regimen Containing the HCV NS3/4A Protease Inhibitor Faldaprevir, the Non-nucleoside NS5B Inhibitor Deleobuvir, and Ribavirin for Genotype-1b-infected Patients
|
| |
| |
Reported by Jules Levin
IDWeek Oct 2-6 2013 San Francisco, CA
Parvez Mantry1, Marcus Schuchmann2, Ansgar W. Lohse3, Keikawus Arasteh4, Michael Manns5, Thomas Berg6, Stefan Mauss7, Michael Geissler8, Federico Mensa9, Wulf O. Bocher10, Stefan Zeuzem11
1The Liver Institute at Methodist Dallas Medical Center, Dallas, TX; 2University Hospital Mainz, Mainz, Germany; 3University Hospital Hamburg-Eppendorf, Hamburg, Germany; 4EPIMED - GmbH Berlin, Germany; 5Hannover Medical School, Hannover, Germany; 6University Hospital Leipzig, Leipzig, Germany;
7Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 8Esslingen Hospital, Esslingen, Germany; 9Boehringer Ingelheim, Ridgefield, CT, USA; 10Boehringer Ingelheim, Biberach, Germany; 11J. W. Goethe University Hospital, Frankfurt am Main, Germany
|
| |
|
|
|
|
|
